










































Methylcellulose as a scaffold in the culture of liver-organoids for
the potential of treating acute live failure
Citation for published version:
Chandrashekran, A, Mitry, RR, Prema-chandra, T, Starling, C, Lehec, S, Iansante, V, Fitzpatrick, E, Filippi,
C, Deheragoda, M, Hay, D & Dhawan, A 2018, 'Methylcellulose as a scaffold in the culture of liver-
organoids for the potential of treating acute live failure' Cell and Gene Therapy Insights, vol. 4, no. 11, pp.
1087-1103. DOI: 10.18609/cgti.2018.111
Digital Object Identifier (DOI):
10.18609/cgti.2018.111
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Cell and Gene Therapy Insights
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
www.insights.bio   1087
CELL & GENE THERAPY INSIGHTS
Methylcellulose as a scaffold in the 
culture of liver-organoids for the 
potential of treating acute liver failure
Anil Chandrashekran, Ragai R Mitry, Tharindu 
Premachandra, Chris Starling, Sharon Lehec, 
Valeria Iansante, Emer Fitzpatrick, Celine Filippi, 
Maesha Deheragoda, David Hay & Anil Dhawan
Much progress has been made in understanding the development of hu-
man organs through advanced cellular and molecular techniques. Acute 
liver failure (ALF) in children is a life-threatening condition that relies on 
liver or hepatocyte transplantation. The translation of novel regenera-
tive medicine strategies for the treatment of ALF is however somewhat 
limited. Here, we show that in vitro liver-organoids derived from human 
umbilical cord derived mesenchymal stem cells and human cadaveric 
donor-derived hepatocytes, cultured in a clinically appropriate manner, 
exhibit liver function. We obtained organoids that varied in size and mor-
phology which produced albumin, and detoxified ammonium chloride 
into urea. Immunohistochemistry of these organoids revealed hepato-
cyte specific, non-parenchymal markers and histological organisation. 
Our in vitro findings indicate that these organoids may be a useful bridge 
in ALF while awaiting liver recovery or transplant. The organoid culture 
system we have established here is also well suited to drug screening and 
disease modeling.
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INTRODUCTION
There have been significant con-
ceptual and practical advances 
with regards to regenerative med-
icine for the treatment of disease. 
This has ranged from the classic 
use of embryonic stem cells, their 
culture and ability to differentiate 
into practically any cells of the 
body, to reprogramming of fully 
differentiated cells into an embry-
onic state followed by differentia-
tion to a chosen cell type, which 
is now mainstream research [1]. 
These now significantly impact not 
only on treating disease but the po-
tential for modelling disease in cul-
ture dishes that was previously not 
possible. The development of liver 
has been of prominent interest, 
as liver disease is the fifth biggest 
cause of deaths in the UK.
Acute liver failure (ALF) in chil-
dren is a life-threatening condition. 
The prognosis of ALF is generally 
poor and medical intervention re-
lies on a liver [2,3] or hepatocyte 
[4,5] transplantation if the native 
liver is unable to recover. The major 
limitation of the technique today 
is the availability of donor organs. 
Many patients who might benefit 
from a transplant die before a suit-
able organ can be found. Whilst 
much progress has been made in 
the study and understanding of 
the biology of liver [6], there have 
been limited clinical advancements 
in the treatment of ALF utilizing 
novel regenerative techniques, 
such as the use of embryonic stem 
cell techniques to induced pluripo-
tent stem cell-derived hepatocytes. 
Human biocompatible scaffolds 
to grow liver type/functional cells 
is ever increasing. The main chal-
lenges in translating advances in 
basic science of cell therapy into 
the clinic has been determining 
the best route of delivery, the rap-
id elimination of transplanted cells 
by the recipient, poor engraftment 
and proliferation of transplanted 
cells within the liver [7].  
Stem cell-based technologies 
have been extensively researched 
in vitro and in vivo. Mesenchy-
mal stem/stromal cells (MSCs) 
are a population of immature cells 
that can give rise to more mature 
cell types such as adipogenic, os-
teogenic and chondrogenic cells. 
These cells can be easily cultured 
from adult bone marrow and full-
term umbilical cord (blood or the 
Wharton’s jelly). MSCs have also 
been isolated from muscle con-
nective tissue, adipose tissue and 
in some circumstances peripheral 
blood. Culture protocols usually 
include direct plastic adherence 
or enrichment by CD marker se-
lection. The well-established char-
acteristics of MSCs, have been the 
basis of the extensive use in clini-
cal applications. MSCs have been 
used in the treatment of liver dis-
ease with varying results [8]. 
Tissue engineering strategies 
for regenerative medicine are yet 
another avenue of great advance-
ment. Novel scaffolds-engineered 
[9], naturally occurring [10] or syn-
thetic material [11] are under ex-
tensive scrutiny. There is an unmet 
need to use novel organoid-based 
strategies that is suitable for trans-
plantation in ALF until the patient 
receives a liver transplant or the 
native liver recovers. As such, we 
proposed to exploit novel organ-
oid-strategies as a means for clin-
ical application. Here we hypothe-
sized that using methylcellulose as 
a scaffold to obtain liver-organoids 
maybe a useful approach towards 
clinical use.
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RESULTS
Establishment of organoids 
in matrigel
Our initial strategy to develop liver 
organoids, stems from the seminal 
research of Takebe and colleagues 
[12]. Whilst Takebe et al. used 
human induced pluripotent stem 
cell (hiPSC) derived hepatocytes, 
MSCs and human umbilical vein 
endothelial cells (HUVECS) cul-
tured in matrigel with a host of fac-
tors to obtain organoids, we used 
adult hepatocytes from cadaveric 
donors and MSCs cultured in se-
rum free matrigel. Organoids were 
analyzed after 14 days in culture 
(Figure S1A). Confocal imaging of 
these organoids revealed strong 
expression of hepatocyte markers 
(Figure S1B). Our rationale for the 
ratio of cells to be cultured was 
based on our previous experience 
of a 2-D co-culture system of he-
patocytes and MSCs, which result-
ed in improved hepatocyte func-
tion [13]. We tested four different 
ratios of hepatocytes cultured with 
MSCs. Albumin production and 
ability to metabolise ammonium 
chloride to urea were used as func-
tional readouts of the resulting or-
ganoids after two weeks in culture. 
Hepatocytes and MSC cultured 
in a two to one ratio respectively, 
gave rise to the highest albumin 
production (Figure S2A). Interest-
ingly, the urea production was the 
highest when using a one to one 
ratio (Figure S2B). When using a 
two to one ratio of cultured cells, 
these organoids produced albumin 
over a period of 2 weeks, peaking 
from day 10 onwards (Figure S3A). 
These organoids were also able to 
metabolise ammonium chloride to 
produce urea from day 4 peaking 
at day 14 as well (Figure S3B).
Establishing organoids using 
methylcellulose as a scaffold
Matrigel whilst proving to be an 
excellent scaffold for studying and 
understanding basic biology of or-
gan development, its clinical appli-
cation is somewhat restricted as it is 
a gelatinous substance derived from 
Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma cells. Therefore, 
we hypothesized that substituting 
matrigel with methylcellulose as a 
scaffold for the growth of organoids 
might be a useful approach to using 
organoids for future clinical appli-
cation (Figure S4). Having studied 
the composition of growth factors 
present in matrigel (Corning), we 
tested the effects of transforming 
growth factor-β (TGF-β), hepato-
cyte growth factor (HGF) and 
epidermal growth factor (EGF); 
individually and in combination, 
in methylcellulose for the ability 
to produce organoids. A two-part 
hepatocyte to one-part MSC ra-
tio were maintained and cultured 
in the presence of methylcellulose 
and growth factors in non-tissue 
culture 6-well plates. When we cul-
tured MSC and hepatocytes with a 
single cytokine only, no organoids 
formed (Figure 1A) 14 days into 
culture. However, the combination 
of TGF-β and EGF growth factor 
gave rise to organoids of varying 
sizes  (50–600μm) (Figure 1B). Sur-
prisingly, the addition of all three 
growth factors in culture yielded or-
ganoids that weren’t as big in com-
parison to organoids from TGF-β 
and EGF growth factor combina-
tion (Figure 1C). The combination 
of TGF-β and EGF growth factor 
(Figure 1B) cultured organoids were 
macroscopic after 14 days in cul-
ture, varying in shapes and sizes 
(Figure 1D).
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 f FIGURE 1
Morphology of organoids grown in methylcellulose.
(A) Left hand panel: hepatocytes and MSCs cultured in a 2:1 ratio respectively in EGF only; right hand panel: as in left hand panel 
but at higher magnification. No organoid formation was observed after 14 days in culture. Scale bar = 100 micron. (B) Left hand 
panel: organoids obtained from hepatocytes and MSCs cultured in a 2:1 ratio respectively in EGF and TGF-β; right hand panel: as 
in left hand panel but at higher magnification. Organoids formation was observed after 14 days from culture initiation Scale bar = 
100 micron. (C) Left hand panel: organoids obtained from hepatocytes and MSCs cultured in a 2:1 ratio respectively in EGF, HGF 
and TGF-β; right hand panel: as in left hand panel but at higher magnification. Organoids formation was observed after 14 days from 
culture initiation, however morphologically not the same as in B. Scale bar = 100 micron. (D) Organoids grown in non-tissue culture 
treated 6-well plates. After 2 weeks in culture many were macroscopic and heterogenous in shape. Scale bar = 200 micron. 
RESEARCH ARTICLE 
  1091Cell & Gene Therapy Insights - ISSN: 2059-7800  
Liver function activities 
of organoids cultured in 
methylcellulose
We next tested the ability of organ-
oids to produce albumin and detoxi-
fy ammonium chloride, in optimally 
cultured in the conditions. We com-
pared these conditions, to that of or-
ganoids obtained using matrigel as a 
reference point. Albumin production 
was highest from organoids derived 
from cultures containing TGF-β and 
EGF (Figure 2A). Again, surprisingly, 
organoids derived from the culture in 
all three growth factors, yielded the 
least amount albumin production. 
This pattern of albumin production 
co-related with the morphology of 
organoids obtained as above. When 
organoids were assayed for the abil-
ity to detoxify ammonium chloride 
to urea, a similar pattern was ob-
served. Urea production was highest 
from organoids derived from the cul-
ture containing TGF-β and EGF in 
comparison to the organoids derived 
from all three growth factors (Figure 
2B). A similar co-relation of function 
to morphology was observed.
Histological & biochemical 
properties of organoids de-
rived from methylcellulose
Having established the function-
ality of these organoids, we then 
analysed the histology of these op-
timally cultured organoids. These 
organoids expressed hepatocyte 
specific marker, OCH1E5 and; bil-
iary marker, cytokeratin 7 (Figure 
3B) and Control H&E section (Fig-
ure 3A) indicating that cells of both 
hepatocyte and biliary lineages were 
present in the organoids. These or-
ganoids also expressed Cytokera-
tin 19 (Figure 3B, left  and middle 
panels). Furthermore, confocal, 
microscopy also revealed CD31 
expression in these organoids sug-
gesting endothelial cell formation 
(Figure 3C).
Finally, we assessed the ability 
of organoids to conjugate biliru-
bin. Albeit relatively lower levels 
compared to the HepG-2 cell line, 
these organoids could conjugate 
bilirubin (Figure 4A). Strikingly, 
we found the expression of MRP-
2 in these organoids, suggesting an 
attempt at organisation of the he-
patocytes into a lobule (Figure 4B, 
middle panel) and compellingly, 
bile staining as shown in a Fouchet 
stain (Figure 4C).
DISCUSSION
In this study, we show that meth-
ylcellulose, an inert semi-solid me-
dia, could be utilized as a scaffold 
to establish liver-organoids that re-
semble liver structure and function. 
The results we obtained here are 
comparable to that of using matri-
gel as a scaffold. There was also a 
good correlation of the morpholo-
gy of organoids obtained to func-
tional activity. Albeit the lowered 
functional activities (albumin and 
urea production) using methylcel-
lulose as opposed to matrigel, the 
suitability of using methylcellulose 
towards clinical grade expansion 
of organoids is highly compelling. 
Further optimization and scal-
ing up of the process is under-
way. Methylcellulose is a synthetic 
chemical product derived from 
cellulose. Cellulose is heated with 
sodium hydroxide and the result-
ing substitution of hydroxyl resi-
dues on cellulose are replaced with 
methoxide [14]. Methylcellulose is 
used in a wide array of applications 
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 f FIGURE 2
Albumin secretion and urea production from organoids.
Albumin secretion from organoids was measured by ELISA method. (A) Albumin production from organoids cultured in Matrigel 
(as a base line) was compared to that which was cultured in methylcellulose. The combination of TGF-β and EGF growth factors in 
methylcelluose yielded the highest amounts of albumin production compared to other cytokine combinations in methycellulose (n 
= 3 independent experiments, each performed in triplicate). (B) Urea production of similar organoids were measured by colorimetric 
means. Here too the combination of TGF-β and EGF growth factors yielded the highest amounts of urea production compared to 
other cytokine combinations in methylcellulose (n = 3 independent experiments, each performed in triplicate).
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in industry and in the clinic. It is a 
well-known agent for the treatment 
of constipation [15] and its deriva-
tives can be used as artificial tears 
[16,17] or saliva. In the laboratory, 
methylcellulose has long been used 
as a scaffold for the development 
of colony forming cells from hae-
matopoietic stem/progenitor cells 
and is a good support for studying 
stem cell proliferation and differen-
tiation [18–20]. As such, it should 
be relatively easy to implement a 
clinical grade strategy using meth-
ylcellulose as a scaffold to obtain 
liver-organoids.
A further advantage to using 
methylcellulose as a scaffold is the 
flexibility to assess the effects of dif-
ferent growth factors, tailor-made 
chemicals or synthetic combina-
tions on organoid formation. We 
found that the use of EGF and 
TGF-β together were crucial in 
establishing organoids. EGF is 
a member of the tyrosine kinase 
 f FIGURE 3
Immunohistochemical profile of organoids.
Immunohistochemistry was performed to characterize organoids. (A) Organoids stained by H&E (left hand panel), and organoids 
expressing hepatocyte (Orange arrow) and biliary marker (blue arrow)(right hand panel). (B) Organoids expressing CK-19 (left and 
middle panel) and control H&E stained sections of a liver biopsy (right hand panel). (C) Organoids expressing CD31 (green) and 
nuclear stained DAPI (blue).
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 f FIGURE 4
Organoids exhibiting biliary function.
(A) Organoids were able to conjugate bile as in control cells, as measured biochemically. (B) Immunohistochemistry confirmed this 
as organoids stained positively for MRP-2 antibody (middle panel), H&E left panel and control tissue (right panel) thus suggesting 
structure formation. (C) Fouchet staining of organoids showing bile stain, indicating the presence of conjugated bile.
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receptor family [21] and is import-
ant in the upregulation of MAP 
kinase signalling pathway leading 
to DNA synthesis and cell prolif-
eration [22]. TGF-β on the other 
hand is a growth factor known to 
induce apoptosis in lymphocytes 
and hepatocytes in mice [23]. It is 
also thought to stop proliferation 
and induce differentiation in stem 
cells [24]. It is intriguing that the 
synergistic effect of EGF and TGF-
βin our experiments was necessary 
for the formation of organoids, to 
which the exact mechanism of or-
ganoid development remains to be 
determined. The simplicity of this 
system means that it can also be 
scaled up for drug screening and 
cell signalling experiments as well. 
We and others have previously 
shown that hepatocytes isolated 
from a donor liver, can be used to 
treat children with ALF effective-
ly [25–27]. Further improvements 
to hepatocyte transplantation has 
been the method of encapsulating 
hepatocytes with alginate beads 
[28,29]. This encapsulating method 
eliminates the need for immuno-
suppressing drugs that are routinely 
used in liver or non-encapsulated 
hepatocyte transplantation. Such 
alginate encapsulated human he-
patocyte transplants in humans 
although not necessarily curative, 
have shown to be useful as a bridge 
to native liver recovery or until a 




niques have been developed using 
3D plotting with methylcellulose 
and alginate. MSCs cultured in these 
3D scaffolds retained viability and 
differentiation properties [30,31]. 
Taken together, it is highly conceiv-
able to be able to establish organoids 
in methylcellulose, as done here and 
then encapsulating the resulting or-
ganoids in alginate-methylcellulose 
3D scaffolds [32]. Such a strategy 
should be highly applicable in the 
treatment of ALF. 
METHODS 
Hepatocyte & MSC isolation
Primary hepatocyte isolation and 
research activities were ethically ap-
proved via the National Research 
Ethics Service (King’s College Hos-
pital local research ethics committee; 
LREC 01-016). Organs were donat-
ed through the National Health Ser-
vice Blood and Transplant (NHSBT) 
and offered for hepatocyte transplan-
tation and/or research following de-
cline for solid organ transplantation. 
Hepatocytes were derived from do-
nor as previously described [33]. All 
hepatocyte isolation procedures were 
performed to Good Manufacturing 
Practises (GMP) standards (Cell 
Therapy Unit, King’s College Hospi-
tal) and governed by the Human Tis-
sue Authority for the storage, clinical 
and research use of these cells. Brief-
ly, surgically obtained split liver lobes 
were weighed and cannulated [26]. 
This was followed a by an in-house 
modified collagenase perfusion step, 
followed by a perfusion to inactivate 
the collagenase. Perfused liver lobes 
were then macerated using scissors 
and forceps and filtered through 
gauze until clumps had reduced. He-
patocytes were obtained by centrifu-
gation at 50g, where the hepatocyte 
fraction was collected from the cell 
pellet. Cell number and viability was 
determined by trypan blue exclu-
sion. Cells were frozen in cryovials 
(research use) and cryobags (clinical 
use), using a controlled rate freezer 
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and stored at -180°C vapour phase 
nitrogen freezers. 
MSCs were isolated from Whar-
ton’s jelly (WJ) of umbilical cords 
obtained following caesarean sec-
tion deliveries at King’s College 
Hospital. These umbilical cords 
were procured via the Anthony 
Nolan Trust, according to King’s 
College Hospital Institutional 
guidelines. MSCs were isolated 
at research laboratory grade stan-
dards. Briefly, cords were collected 
in PBS containing 40μg/ml of gen-
tamicin [34]. Cords were cut into 
sections to expose the WJ, which 
was minced into fine pieces (1–3 
mm2). The explants were placed in 
sterile petri dishes and immersed 
with MSC culture medium, con-
sisting of MEM a (Life Technol-
ogies), 5% Stemulate (Cook Re-
gentec), 40μg/ml of gentamicin 
and allowed to adhere for up to 5 
minutes. Cord samples were then 
incubated at 37°C, 5% CO2 in at-
mosphere and half medium replen-
ished every 3–6 days. Gentamicin 
was used in the MSC medium for 
the first 1–2 weeks of culture and 
then replaced by penicillin/strepto-
mycin (100 units/ml and 100 μg/
ml, respectively). Once cell cultures 
were established, they were expand-
ed, quality controlled and cryopre-
served. Cells were positive for MSC 
markers (i.e., CD73, CD90 and 
CD105; expression higher than 
75%) and negative for hematopoi-
etic markers (i.e., CD14, CD34 
and CD45; expression lower than 
2%) by flow cytometry.
Organoid formation
The initial establishment of liver 
organoids was adapted from Takebe 
et al. Briefly, hepatocytes and MSC 
were thawed and cultured in round 
bottom non-tissue culture treated 
96 well plates. The culture media 
consisted of DMEM/F12 high 
glucose (Gibco) as the basal me-
dia supplemented with N2 (Gib-
co) and B27 (Gibco) supplements, 
Penicillin and Streptomycin and 
L-glutamine. Matrigel (Corning) 
was added to a final concentration 
of 1%. The initial ratio of hepato-
cytes to MSC was 1:1 and 105 cells 
in 200 μl total volume used. Plates 
were incubated at 37°C, 5% CO2 
in atmosphere. Different cell ratios 
were investigated. Plates were cul-
tured for 2 weeks and monitored 
daily for the growth of organoids.
Having established the system 
in Matrigel, methylcellulose (Bio-
Techne) was substituted as a scaf-
fold. We also scaled up the process 
into non-tissue culture treated six 
well plates, omitting the use of 
Penicillin and Streptomycin. Meth-
ylcellulose was added to a similar 
culture media as above to a final 
concentration of 1.2%. 10ng/ml fi-
nal concentration of TGF-β, HGF 
and EGF (all from BioTechne) was 
used in cultures, either individually 
and/or in combination. Plates were 
incubated at 37°C in 5% CO2 in 
atmosphere. Plates were cultured 
for 2 weeks and monitored daily for 
the growth of organoids.
Albumin assay 
Albumin secretion from organoids 
were measured by a standard ELI-
SA protocol as previously described 
[13]. Briefly, organoids were trans-
ferred to fresh plates and incubated 
with media (less the scaffold) for 8 
to 18 hours, and media was then 
removed and stored at -20°C until 
the assay. 
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Urea assay
Urea assay was performed according 
to previously established methods 
[13]. Again, organoids were trans-
ferred to new plates and incubated 
with media (less scaffold) in the pres-
ence of 4mM Ammonium Chloride. 
Urea production in the media was 
measured 6 hours later using Quan-
tiChrome Urea Assay Kit (BioAssay 
Systems, Cambridge, UK).
Bile conjugation assay
Total and conjugated bile was de-
termined by using a bilirubin assay 
kit from Sigma. One μM unconju-
gated bilirubin was used to spike 
organoids. This assay is based on 
the Jendrassik-Grof method which 
utilizes the reaction of bilirubin 
with diazotized sulfonic acid result-
ing in a colorimetric product mea-
sured at 530 nm, proportionate to 
the bilirubin present in the sample. 
Histology
Developing and established or-
ganoids were fixed in 4% parafor-
maldehyde. Fixed organoids were 
embedded in 2.5% agarose. The 
set agarose-organoid material was 
then routinely processed. Five-mi-
cron thin paraffin embedded sec-
tions were placed on poly-lysine 
coated slides. Standard immuno-
histochemistry protocols were em-
ployed. Details of antibodies used 
in Table S1. All immune-stained 
sections were counter stained with 
Haematoxylin and permanently 
mounted.
Confocal microscopy was per-
formed on live organoids mildly 
permeabilised with 0.01% triton-x 
in PBS. Organoids were then 
stained with respective antibodies 
(Table S1), washed twice in PBS and 
mounted onto glass slides. Confo-
cal microscopy was performed on a 
Leica SP5 microscope.
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Figure S1 Organoids cultured in matrigel
A. Morphology of organoids from a 96-well plate
B. Confocal imaging of hepatocyte (top right panel, in green) and CD105 marker (bottom left panel-in 
red and merged image (bottom right panel). Dapi stain of nuclei (Top left panel-in blue)
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Figure S2 Cell ratio analysis for organoid development
A. Albumin ELISA demonstrating that a 2:1 hepatocyte: MSC ratio gave rise to the highest expression
B. Urea production was highest using a 1:1 hepatocyte: MSC ratio
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Figure S3 Time function of organoids
A. Albumin production was detected from day two in culture and peaking at day 10
B. Urea production was like albumin production except that a slightly higher level was noted on day 2. 
Urea production peaked at day 12
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Figure S4 Schematic production for developing organoids suitable for transplantation
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Table S1. Antibodies used in this study 





























CD31 Abcam ab28364 - 1:50 - - Endothe-
lial cells 
+ve
CD105-PE Biolegend 323205 - 1:50 - MSC-P1 MSC +ve
